The optimal activation of dendritic cells (DCs) by tumor antigens is critical for the efficacy of therapeutic cancer vaccine, which further results in intense and durable responses of CD4+ T lymphocytes and cytotoxic CD8+ T lymphocytes, as well as the enhanced infiltration in the tumor microenvironment (TME) (29). The gene discussed is CD8A; the disease is neoplasm.